HDT Bio is a clinical stage private company developing advanced products to treat and prevent cancer and infectious diseases. Utilizing our proprietary LION™ technology, our products feature superior safety, potency, durability, and manufacturing advantages.
HDT Bio is a clinical stage private company developing advanced products to treat and prevent cancer and infectious diseases. Utilizing our proprietary LION™ technology, our products feature superior safety, potency, durability, and manufacturing advantages
HDT Bio is a clinical stage private company developing advanced products to treat and prevent cancer and infectious diseases. Utilizing our proprietary LION™ technology, our products feature superior safety, potency, durability, and manufacturing advantages
HDT Bio’s proprietary technologies harness the immune system to combat difficult-to-treat conditions and improve patient lives worldwide.
The next generation of formulations
HDT’s LION™ technology provides increased potency compared to traditional formulations – increasing safety, tolerability, immunogenicity, and manufacturability.
Latest News
FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease
SEATTLE, Sept. 19, 2025 /PRNewswire/ -- HDT Bio Corporation, a U.S.-based clinical-stage biotechnology company advancing immune-enhancing solutions for global health, biodefense, and oncology, today announced that the U.S. Food and Drug Administration (FDA) has...
MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
HDT Bio's LION™ platform to support malaria vaccine development by MalarVx SEATTLE, Jan. 15, 2025 /PRNewswire/ -- MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid...
Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
Click here to view article